Ranbaxy gets FDA approval to market Doxycycline tablets

By Elaine Rigoli

Tampa, Fla., June 2 - Ranbaxy Laboratories Ltd. has received approval from the Food and Drug Administration to manufacture and market Doxycycline tablets 50 mg, 75 mg and 100 mg.

Ranbaxy said the FDA has determined the company's formulations have the same therapeutic effect as that of the branded drug Adoxa, marketed by Bioglan Pharmaceutical Co.

Doxycycline is indicated for a variety of infections when caused by susceptible strains or microorganisms including respiratory tract and urinary tract infections, skin and skin structure infections and severe acne as adjunctive therapy.

Ranbaxy is an international pharmaceutical company based in Haryana, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.